Stock TSVT 2SEVENTY BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings 2seventy bio, Inc.

Equities

TSVT

US9013841070

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
4.27 USD -7.78% Intraday chart for 2seventy bio, Inc. -15.61% 0.00%
Apr. 19 US FDA mandates label updates on CAR-T cancer therapies RE
Apr. 05 Bristol-Myers Squibb, 2seventy Bio Say FDA Approves Expansion of Myeloma Treatment's Indication MT

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
2SEVENTY BIO, INC. Stock 2seventy bio, Inc.
0.00% 219M -
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+4.09% 43.84B
B
LONZA GROUP AG Stock Lonza Group AG
+46.17% 41.25B
A
MODERNA, INC. Stock Moderna, Inc.
+9.45% 41.68B
B-
CELLTRION, INC. Stock Celltrion, Inc.
-10.92% 27.04B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.32% 25.53B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.87% 18.18B
B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.70% 12.29B
C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
+1.28% 12.29B
C+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.78% 11.15B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. TSVT Stock
  4. Ratings 2seventy bio, Inc.